Schedule 13D ownership disclosure
SAB Biotherapeutics, Inc.
Common Stock, $0.0001 par value per share · CUSIP: 78397T202
Event date: 2025-09-26
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- RA Capital Management, L.P.Reported CIK 0001346824
Shares: 4,401,500.00 · Class: 9.9%
- Peter KolchinskyReported CIK 0001384859
Shares: 4,401,500.00 · Class: 9.9%
- Rajeev ShahReported CIK 0001619841
Shares: 4,401,500.00 · Class: 9.9%
- RA Capital Healthcare Fund, L.P.Reported CIK 0001315082
Shares: 4,401,500.00 · Class: 9.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001346824-25-000015
- Form type
- SCHEDULE 13D
- Filer
- RA CAPITAL MANAGEMENT, L.P.
- CIK
- CIK 1346824
- Filed
- Oct 03, 2025
- Reporting period
- Sep 26, 2025
- Description
- Schedule 13D beneficial ownership